In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
As of close of business last night, Aclaris Therapeutics Inc’s stock clocked out at $1.22, up 1.67% from its previous closing price of $1.20. In other words, the price has increased by $1.67 from its previous closing price. On the day, 0.65 million shares were traded. ACRS stock price reached its highest trading level at $1.22 during the session, while it also had its lowest trading level at $1.1817.
Ratios:
To gain a deeper understanding of ACRS’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.16 and its Current Ratio is at 4.16. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
On October 03, 2023, Evercore ISI started tracking the stock assigning a Outperform rating and target price of $22.Evercore ISI initiated its Outperform rating on October 03, 2023, with a $22 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 04 ’24 when Powell Andrew Kenneth William bought 6,000 shares for $1.25 per share. The transaction valued at 7,500 led to the insider holds 28,863 shares of the business.
Powell Andrew Kenneth William bought 8,500 shares of ACRS for $10,455 on Mar 01 ’24. The Director now owns 22,863 shares after completing the transaction at $1.23 per share. On Oct 23 ’23, another insider, Monahan Joseph, who serves as the Chief Scientific Officer of the company, sold 6,000 shares for $5.08 each. As a result, the insider received 30,460 and left with 129,724 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ACRS now has a Market Capitalization of 86528504 and an Enterprise Value of -29077448. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.78 while its Price-to-Book (P/B) ratio in mrq is 0.55. Its current Enterprise Value per Revenue stands at -0.931 whereas that against EBITDA is 0.247.
Stock Price History:
The Beta on a monthly basis for ACRS is 0.24, which has changed by -0.86368716 over the last 52 weeks, in comparison to a change of 0.24191546 over the same period for the S&P500. Over the past 52 weeks, ACRS has reached a high of $11.12, while it has fallen to a 52-week low of $0.59. The 50-Day Moving Average of the stock is 0.02%, while the 200-Day Moving Average is calculated to be -67.63%.
Shares Statistics:
It appears that ACRS traded 1.09M shares on average per day over the past three months and 793150 shares per day over the past ten days. A total of 70.89M shares are outstanding, with a floating share count of 64.78M. Insiders hold about 9.10% of the company’s shares, while institutions hold 88.61% stake in the company. Shares short for ACRS as of 1713139200 were 4992194 with a Short Ratio of 4.58, compared to 1710460800 on 5122089. Therefore, it implies a Short% of Shares Outstanding of 4992194 and a Short% of Float of 8.1099994.
Earnings Estimates
Investors are keenly observing as 7.0 analysts analyze and rate the current performance of Aclaris Therapeutics Inc (ACRS) in the stock market.On average, analysts expect EPS of -$0.29 for the current quarter, with a high estimate of -$0.08 and a low estimate of -$0.37, while EPS last year was -$0.42. The consensus estimate for the next quarter is -$0.25, with high estimates of -$0.08 and low estimates of -$0.35.
Analysts are recommending an EPS of between -$0.32 and -$1.35 for the fiscal current year, implying an average EPS of -$0.99. EPS for the following year is -$0.82, with 7.0 analysts recommending between -$0.31 and -$1.49.
Revenue Estimates
For the next quarter, 6 analysts are estimating revenue of $1.37M. There is a high estimate of $1.87M for the next quarter, whereas the lowest estimate is $570k.
A total of 6 analysts have provided revenue estimates for ACRS’s current fiscal year. The highest revenue estimate was $7.48M, while the lowest revenue estimate was $2.26M, resulting in an average revenue estimate of $5.58M. In the same quarter a year ago, actual revenue was $31.25MBased on 6 analysts’ estimates, the company’s revenue will be $6M in the next fiscal year. The high estimate is $7.8M and the low estimate is $2.26M.
